{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T13:55:07Z","timestamp":1648994107969},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,12,7]],"date-time":"2012-12-07T00:00:00Z","timestamp":1354838400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z. Rheumatol."],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1007\/s00393-011-0885-4","type":"journal-article","created":{"date-parts":[[2012,12,5]],"date-time":"2012-12-05T15:29:43Z","timestamp":1354721383000},"page":"49-58","source":"Crossref","is-referenced-by-count":1,"title":["Personalisierte Medizin bei der rheumatoiden Arthritis"],"prefix":"10.1007","volume":"72","author":[{"given":"E.","family":"Feist","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"D\u00f6rner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,12,7]]},"reference":[{"key":"885_CR1","doi-asserted-by":"crossref","unstructured":"Choy EH et al (2002) Repeat-cycle study of high-dose intravenous 4162W94 anti-CD4 humanized monoclonal antibody in rheumatoid arthritis. A randomized placebo-controlled trial. Rheumatology (Oxford) 41:1142\u20131148","DOI":"10.1093\/rheumatology\/41.10.1142"},{"key":"885_CR2","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1093\/rheumatology\/35.3.231","volume":"35","author":"Isaacs","year":"1996","unstructured":"Isaacs JD et al (1996) CAMPATH-1H in rheumatoid arthritis\u2013an intravenous dose-ranging study. Br J Rheumatol 35:231\u2013240","journal-title":"Br J Rheumatol"},{"key":"885_CR3","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1002\/1529-0131(200109)44:9<1998::AID-ART348>3.0.CO;2-T","volume":"44","author":"Isaacs","year":"2001","unstructured":"Isaacs JD et al (2001) Morbidity and mortality in rheumatoid arthritis patients with prolonged and profound therapy-induced lymphopenia. Arthritis Rheum 44:1998\u20132008","journal-title":"Arthritis Rheum"},{"key":"885_CR4","doi-asserted-by":"crossref","unstructured":"Edwards JC, Cambridge G (2001) Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 40:205\u2013211","DOI":"10.1093\/rheumatology\/40.2.205"},{"key":"885_CR5","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1136\/annrheumdis-2011-200170","volume":"71","author":"Tak","year":"2012","unstructured":"Tak PP et al (2012) Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE. Ann Rheum Dis 71:351\u2013357","journal-title":"Ann Rheum Dis"},{"key":"885_CR6","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","volume":"54","author":"Cohen","year":"2006","unstructured":"Cohen SB et al (2006) Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54:2793\u20132806","journal-title":"Arthritis Rheum"},{"key":"885_CR7","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","volume":"54","author":"Emery","year":"2006","unstructured":"Emery P et al (2006) The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54:1390\u20131400","journal-title":"Arthritis Rheum"},{"key":"885_CR8","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","volume":"350","author":"Edwards","year":"2004","unstructured":"Edwards JC et al (2004) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350:2572\u20132581","journal-title":"N Engl J Med"},{"key":"885_CR9","doi-asserted-by":"crossref","first-page":"917","DOI":"10.3899\/jrheum.090442","volume":"37","author":"Mease","year":"2010","unstructured":"Mease PJ et al (2010) Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial. J Rheumatol 37:917\u2013927","journal-title":"J Rheumatol"},{"key":"885_CR10","doi-asserted-by":"crossref","first-page":"R75","DOI":"10.1186\/ar3337","volume":"13","author":"Tony","year":"2011","unstructured":"Tony HP et al (2011) Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). Arthritis Res Ther 13:R75","journal-title":"Arthritis Res Ther"},{"key":"885_CR11","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/art.30233","volume":"63","author":"Sellam","year":"2011","unstructured":"Sellam J et al (2011) B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study. Arthritis Rheum 63:933\u2013938","journal-title":"Arthritis Rheum"},{"key":"885_CR12","first-page":"191","volume":"6","author":"Kekow","year":"2012","unstructured":"Kekow J, Mueller-Ladner U, Schulze-Koops H (2012) Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNFalpha blocker failure. Biologics 6:191\u2013199","journal-title":"Biologics"},{"key":"885_CR13","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.autrev.2006.03.008","volume":"6","author":"Venrooij","year":"2006","unstructured":"Venrooij WJ van, Zendman AJ, Pruijn GJ (2006) Autoantibodies to citrullinated antigens in (early) rheumatoid arthritis. Autoimmun Rev 6:37\u201341","journal-title":"Autoimmun Rev"},{"key":"885_CR14","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1002\/art.22817","volume":"56","author":"Bang","year":"2007","unstructured":"Bang H et al (2007) Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis Rheum 56:2503\u20132511","journal-title":"Arthritis Rheum"},{"key":"885_CR15","doi-asserted-by":"crossref","first-page":"R12","DOI":"10.1186\/ar2362","volume":"10","author":"Ursum","year":"2008","unstructured":"Ursum J et al (2008) Antibodies to mutated citrullinated vimentin and disease activity score in early arthritis: a cohort study. Arthritis Res Ther 10:R12","journal-title":"Arthritis Res Ther"},{"key":"885_CR16","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/art.24390","volume":"61","author":"Lopez-Longo","year":"2009","unstructured":"Lopez-Longo FJ et al (2009) Association between anti-cyclic citrullinated peptide antibodies and ischemic heart disease in patients with rheumatoid arthritis. Arthritis Rheum 61:419\u2013424","journal-title":"Arthritis Rheum"},{"key":"885_CR17","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1136\/ard.2007.076521","volume":"66","author":"Turesson","year":"2007","unstructured":"Turesson C, Eberhardt K, Jacobsson LT, Lindqvist E (2007) Incidence and predictors of severe extra-articular disease manifestations in an early rheumatoid arthritis inception cohort. Ann Rheum Dis 66:1543\u20131544","journal-title":"Ann Rheum Dis"},{"key":"885_CR18","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","volume":"69","author":"Aletaha","year":"2010","unstructured":"Aletaha D et al (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69:1580\u20131588","journal-title":"Ann Rheum Dis"},{"key":"885_CR19","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"Aletaha","year":"2010","unstructured":"Aletaha D et al (2010) 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62:2569\u20132581","journal-title":"Arthritis Rheum"},{"key":"885_CR20","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1172\/JCI60975","volume":"122","author":"Harre","year":"2012","unstructured":"Harre U et al (2012) Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentin. J Clin Invest 122:1791\u20131802","journal-title":"J Clin Invest"},{"key":"885_CR21","doi-asserted-by":"crossref","unstructured":"Rubbert-Roth A et al (2010) Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR). Rheumatology (Oxford) 49:1683\u20131693","DOI":"10.1093\/rheumatology\/keq116"},{"key":"885_CR22","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1136\/ard.2009.119933","volume":"69","author":"Emery","year":"2010","unstructured":"Emery P et al (2010) Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab\u2019s Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis 69(9):1629\u20131635","journal-title":"Ann Rheum Dis"},{"key":"885_CR23","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1136\/annrheumdis-2011-200003","volume":"71","author":"Chatzidionysiou","year":"2012","unstructured":"Chatzidionysiou K et al (2012) Effectiveness of disease-modifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration. Ann Rheum Dis 71:374\u2013377","journal-title":"Ann Rheum Dis"},{"key":"885_CR24","doi-asserted-by":"crossref","first-page":"101ra92","DOI":"10.1126\/scitranslmed.3002432","volume":"3","author":"Owczarczyk","year":"2011","unstructured":"Owczarczyk K et al (2011) A plasmablast biomarker for nonresponse to antibody therapy to CD20 in rheumatoid arthritis. Sci Transl Med 3:101ra92","journal-title":"Sci Transl Med"},{"key":"885_CR25","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1002\/art.23473","volume":"58","author":"Roll","year":"2008","unstructured":"Roll P, Dorner T, Tony HP (2008) Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. Arthritis Rheum 58:1566\u20131575","journal-title":"Arthritis Rheum"},{"key":"885_CR26","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3899\/jrheum.090856","volume":"37","author":"Vollenhoven","year":"2010","unstructured":"Vollenhoven RF van et al (2010) Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol 37:558\u2013567","journal-title":"J Rheumatol"},{"key":"885_CR27","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1136\/ard.2010.144998","volume":"70","author":"Buch","year":"2011","unstructured":"Buch MH et al (2011) Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 70:909\u2013920","journal-title":"Ann Rheum Dis"},{"key":"885_CR28","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/art.34331","volume":"64","author":"De","year":"2012","unstructured":"De Vita S et al (2012) A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis. Arthritis Rheum 64:843\u2013853","journal-title":"Arthritis Rheum"},{"key":"885_CR29","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S1470-2045(09)70161-5","volume":"10","author":"Carson","year":"2009","unstructured":"Carson KR et al (2009) Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 10:816\u2013824","journal-title":"Lancet Oncol"},{"key":"885_CR30","doi-asserted-by":"crossref","first-page":"iii64","DOI":"10.1136\/ard.2008.097972","volume":"67","author":"Calabrese","year":"2008","unstructured":"Calabrese LH, Molloy ES (2008) Progressive multifocal leucoencephalopathy in the rheumatic diseases: assessing the risks of biological immunosuppressive therapies. Ann Rheum Dis 67(Suppl 3):iii64\u201365","journal-title":"Ann Rheum Dis"},{"key":"885_CR31","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/acr.21641","volume":"Res","author":"Singh","year":"2012","unstructured":"Singh JA et al (2012) 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 64:625\u2013639","journal-title":"Arthritis Care"},{"key":"885_CR32","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1600-0609.2004.00214.x","volume":"72","author":"Kimby","year":"2004","unstructured":"Kimby E, Sverrisdottir A, Elinder G (2004) Safety of rituximab therapy during the first trimester of pregnancy: a case history. Eur J Haematol 72:292\u2013295","journal-title":"Eur J Haematol"},{"key":"885_CR33","first-page":"1426","volume":"91","author":"Friedrichs","year":"2006","unstructured":"Friedrichs B et al (2006) The effects of rituximab treatment during pregnancy on a neonate. Haematologica 91:1426\u20131427","journal-title":"Haematologica"},{"key":"885_CR34","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1136\/ard.2007.074773","volume":"67","author":"Genovese","year":"2008","unstructured":"Genovese MC et al (2008) Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis 67:547\u2013554","journal-title":"Ann Rheum Dis"},{"key":"885_CR35","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1002\/art.21201","volume":"52","author":"Kremer","year":"2005","unstructured":"Kremer JM et al (2005) Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52:2263\u20132271","journal-title":"Arthritis Rheum"},{"key":"885_CR36","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1056\/NEJMoa035075","volume":"349","author":"Kremer","year":"2003","unstructured":"Kremer JM et al (2003) Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 349:1907\u20131915","journal-title":"N Engl J Med"},{"key":"885_CR37","doi-asserted-by":"crossref","first-page":"865","DOI":"10.7326\/0003-4819-144-12-200606200-00003","volume":"144","author":"Kremer","year":"2006","unstructured":"Kremer JM et al (2006) Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 144:865\u2013876","journal-title":"Ann Intern Med"},{"key":"885_CR38","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.rdc.2004.02.002","volume":"30","author":"Kremer","year":"2004","unstructured":"Kremer JM (2004) Cytotoxic T-lymphocyte antigen 4-immunoglobulin in rheumatoid arthritis. Rheum Dis Clin North Am 30:381\u2013391, viii","journal-title":"Rheum Dis Clin North Am"},{"key":"885_CR39","doi-asserted-by":"crossref","first-page":"S55","DOI":"10.1097\/01.rhu.0000166626.68898.17","volume":"11","author":"Kremer","year":"2005","unstructured":"Kremer JM (2005) Selective costimulation modulators: a novel approach for the treatment of rheumatoid arthritis. J Clin Rheumatol 11:S55\u201362","journal-title":"J Clin Rheumatol"},{"key":"885_CR40","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.3899\/jrheum.110386","volume":"38","author":"Scarsi","year":"2011","unstructured":"Scarsi M, Ziglioli T, Airo P (2011) Baseline numbers of circulating CD28-negative T cells may predict clinical response to abatacept in patients with rheumatoid arthritis. J Rheumatol 38:2105\u20132111","journal-title":"J Rheumatol"},{"key":"885_CR41","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1136\/ard.2008.091876","volume":"68","author":"Buch","year":"2009","unstructured":"Buch MH et al (2009) Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study. Ann Rheum Dis 68:1220\u20131227","journal-title":"Ann Rheum Dis"},{"key":"885_CR42","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1136\/annrheumdis-2011-200355","volume":"71","author":"Keystone","year":"2012","unstructured":"Keystone EC et al (2012) Abatacept in subjects who switch from intravenous to subcutaneous therapy: results from the phase IIIb ATTUNE study. Ann Rheum Dis 71:857\u2013861","journal-title":"Ann Rheum Dis"},{"key":"885_CR43","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1002\/art.22070","volume":"54","author":"Weinblatt","year":"2006","unstructured":"Weinblatt M et al (2006) Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: a one-year randomized, placebo-controlled study. Arthritis Rheum 54:2807\u20132816","journal-title":"Arthritis Rheum"},{"key":"885_CR44","unstructured":"ATTAIN-Studie, Filipo RM et al (2011) French Society of Rheumatology Congress, 2011, Poster number: 113"},{"key":"885_CR45","unstructured":"Dougados M et al (2011) French Society of Rheumatology Congress, 2011, Poster number: 114"},{"key":"885_CR46","unstructured":"Sibilia J et al (2011) French Society of Rheumatology Congress, 2011, Poster number: 110"},{"key":"885_CR47","unstructured":"Sibilia J (2011) French Society of Rheumatology Congress, 2011, Poster number: 115"},{"key":"885_CR48","unstructured":"H\u00e4upl T et al (2011) Poster EULAR 2011, SAT0274"},{"key":"885_CR49","unstructured":"Tony HP et al (2011) EULAR 2011, Poster number THU0342"},{"key":"885_CR50","unstructured":"Wendler et al (2009) Poster, DGRh 2009, Poster RA2.12"},{"key":"885_CR51","unstructured":"Schiff M et al (2012) EULAR 2012, OP0022"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-011-0885-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-011-0885-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-011-0885-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T12:36:08Z","timestamp":1559046968000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-011-0885-4"}},"subtitle":["Serologisch-klinische Patientenprofile in der Optimierung der B- und T-Zell-gerichteten Therapie"],"short-title":[],"issued":{"date-parts":[[2012,12,7]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["885"],"URL":"https:\/\/doi.org\/10.1007\/s00393-011-0885-4","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,7]]}}}